文献速递药物不良反应与药物警戒

全球个例安全性报告数据库中COVID-19药物不良反应报告的性别差异

Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
PubMed 文献 · Drug Saf · 2020-09-25

本研究从VigiBase数据库中提取截至2020年6月7日的COVID-19治疗药物相关不良反应报告,共纳入2573份报告,聚焦性别的差异。结果显示男性与女性报告的不良反应谱不同,男性常见QT间期延长、腹泻、恶心、肝炎和呕吐,女性常见腹泻、QT间期延长、恶心、呕吐和上腹痛。男性前十位不良反应包含其他肝脏和肾脏相关事件,而女性未报告肝脏或肾脏相关术语。

要点

  • COVID-19药物相关ADR报告存在性别差异,男性与女性报告的不良反应谱不同。
  • 男性报告的前十位ADR包含肝脏和肾脏相关事件,女性则无。
  • COVID-19相关报告模式与这些药物用于非COVID-19适应症时的报告模式不同。

核心结论

  • 全球疑似ADR报告数据库回顾显示,COVID-19治疗药物的不良反应报告模式存在性别差异。
  • ADR性别差异的模式需进一步阐明。

研究设计与样本

  • 从全球ADR数据库VigiBase中提取COVID-19特异性治疗药物的报告,使用算法识别以COVID-19为适应症的报告。
  • 纳入Solidarity试验药物以及任何报告≥100次的药物,并与相同药物用于非COVID-19适应症的报告进行描述性比较。
  • 数据锁定日期为2020年6月7日,共识别2573份COVID-19治疗药物相关报告。

主要发现

  • 男性最常见ADR依次为心电图QT间期延长、腹泻、恶心、肝炎和呕吐。
  • 女性最常见ADR依次为腹泻、心电图QT间期延长、恶心、呕吐和上腹痛。
  • 男性前十位ADR包含其他肝脏和肾脏相关事件,女性前十位未报告肝脏或肾脏相关术语。
  • COVID-19相关报告模式与这些药物非大流行时期的报告模式不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In late 2019, a new coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-was discovered in Wuhan, China, and the World Health Organization later declared coronavirus disease 2019 (COVID-19) a pandemic. Numerous drugs have been repurposed and investigated for therapeutic effectiveness in the disease, including those from "Solidarity," an international clinical trial (azithromycin, chloroquine, hydroxychloroquine, the fixed combination lopinavir/ritonavir, and remdesivir). OBJECTIVE: Our objective was to evaluate adverse drug reaction (ADR) reporting for drugs when used in the treatment of COVID-19 compared with use for other indications, specifically focussing on sex differences. METHOD: We extracted reports on COVID-19-specific treatments from the global ADR database, VigiBase, using an algorithm developed to identify reports that listed COVID-19 as the indication. The Solidarity trial drugs were included, as were any drugs reported ≥ 100 times. We performed a descriptive comparison of reports for the same drugs used in non-COVID-19 indications. The data lock point date was 7 June 2020. RESULTS: In total, 2573 reports were identified for drugs used in the treatment of COVID-19. In order of frequency, the most reported ADRs were electrocardiogram QT-prolonged, diarrhoea, nausea, hepatitis, and vomiting in males and diarrhoea, electrocardiogram QT-prolonged, nausea, vomiting, and upper abdominal pain in females. Other hepatic and kidney-related events were included in the top ten ADRs in males, whereas no hepatic or renal terms were reported for females. COVID-19-related reporting patterns differed from non-pandemic reporting for these drugs. CONCLUSION: Review of a global database of suspected ADR reports revealed sex differences in the reporting patterns for drugs used in the treatment of COVID-19. Patterns of ADR sex differences need further elucidation.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Zekarias A, Watson S, Vidlin SH, et al. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports. Drug Saf. 2020. PMID: 32978702. doi:10.1007/s40264-020-01000-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。